BlinkLab ADHD Study Shows Promise as Dx2 U.S. Program Advances
BB1: $0.625 -0.79% · MC: $106M
BlinkLab reported that its European ADHD study identified 82% of children with ADHD and correctly classified 83% of comparison participants, supporting development of Dx2; the exploratory study is not sufficient for regulatory submission. The company has begun preparing a U.S. pilot study, while its pivotal FDA study for autism product Dx1 remains on track, with completion expected in the current quarter and four research-program readouts expected in the next quarter. BlinkLab held approximately A$16 million in cash at quarter-end.

Comments